Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLT with TIL Therapy in Metastatic Melanoma
NCT07628894Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma, sponsored by City of Hope. Primary endpoint: Adherence at 90 days. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT07628894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628894.